Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858187 | 0.86 | CYP1A2 (0.53) | KDM4EALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3097280 | 0.82 | ALDH1A1 (0.45) | KDM4EALDH1A1ALDH1A3CYP1A2CYP2C9 | |
| SCHEMBL373244 | 0.81 | ERN1 (0.52) | KDM4EALDH1A1CYP3A4ERN1LCK | |
| SCHEMBL1003056 | 0.80 | KDM4E (0.61) | KDM4EALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL398669 | 0.79 | KDM4E (0.60) | KDM4EALDH1A1MAPK1LMNA | |
| SCHEMBL29985579 | 0.79 | KDM4E (0.60) | KDM4EALDH1A1MAPK1LMNA | |
| SCHEMBL21358410 | 0.78 | KDM4E (0.44) | KDM4EALDH1A1ALDH1A3CYP1A2CYP3A4 | |
| SCHEMBL13306818 | 0.78 | CYP1A2 (0.47) | KDM4EALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL261351 | 0.78 | PTGS1 (0.44) | KDM4ECYP1A2CYP3A4CYP2C9ERN1 | |
| SCHEMBL8942444 | 0.78 | ALOX5 (0.56) | KDM4EALDH1A1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273886-B2 | For therapy and prophylaxis of clotting disorders; useful for inhibiting serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein | GENENTECH, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273886-B2 | For therapy and prophylaxis of clotting disorders; useful for inhibiting serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein | GENENTECH, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273886-B2 | For therapy and prophylaxis of clotting disorders; useful for inhibiting serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein | GENENTECH, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070049601-A1 | BENZOFURAN INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049601-A1 | BENZOFURAN INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049601-A1 | BENZOFURAN INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| EP-1626966-A1 | BENZOFURAN INHIBITORS OF FACTOR VIIA | Genentech, Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004113316-A1 | BENZOFURAN INHIBITORS OF FACTOR VIIA | GENENTECH, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113316-A1 | BENZOFURAN INHIBITORS OF FACTOR VIIA | GENENTECH, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040235852-A1 | Benzofuran inhibitors of factor VIIa | GENENTECH, INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235852-A1 | Benzofuran inhibitors of factor VIIa | TFPI, HABP2, SERPINE1 | KDM4E 1398/4885ALDH1A1 604/4885ALDH1A3 3739/4885 |
| US-20070049601-A1 | BENZOFURAN INHIBITORS OF FACTOR VIIa | TFPI, HABP2, F7 | KDM4E 1225/4885ALDH1A1 941/4885ALDH1A3 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.